ZGNX Zogenix Inc.

42.47
+1  (+2%)
Previous Close 41.47
Open 41.56
Price To Book 4.03
Market Cap 1,874,478,344
Shares 44,136,528
Volume 396,897
Short Ratio
Av. Daily Volume 504,301
Stock charts supplied by TradingView

NewsSee all news

  1. Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency

    Safety and efficacy data from a global, retrospective Phase 2 study (RETRO) support potential for deoxynucleoside substrate enhancement therapy (SET) to treat TK2 deficiency, an often-fatal mitochondrial DNA depletion

  2. Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration

    EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application

  3. Zogenix Completes Acquisition of Modis Therapeutics, Inc.

    EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition

  4. INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  5. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 1Q 2020.
ZX008 - (Study 1601)
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Refusal to file Letter (RTF) issued April 8, 2019. NDA resubmission announced September 26, 2019.
FINTEPLA (ZX008)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency

    Safety and efficacy data from a global, retrospective Phase 2 study (RETRO) support potential for deoxynucleoside substrate enhancement therapy (SET) to treat TK2 deficiency, an often-fatal mitochondrial DNA depletion

  2. Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration

    EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application

  3. Zogenix Completes Acquisition of Modis Therapeutics, Inc.

    EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition

  4. INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  5. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  6. Zogenix Announces Acquisition of Modis Therapeutics, Inc.

    Advances Zogenix's strategy to provide transformative therapies to patients and families living with serious rare diseasesAdds MT1621, a proprietary, late-stage investigational medicine targeting Thymidine Kinase 2